Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 8:18:1371601.
doi: 10.3389/fnins.2024.1371601. eCollection 2024.

Use of botulinum toxin in the management of dystonia in Parkinson's disease

Charenya Anandan  1   2 , Joseph Jankovic  1
Affiliations
Review

Use of botulinum toxin in the management of dystonia in Parkinson's disease

Charenya Anandan et al. Front Neurosci. .

Abstract

Botulinum toxin is one of the most potent neurotoxins, but when injected into an overactive muscle, it can transiently alleviate an involuntary movement, such as dystonia. The primary aim of this article is to provide a comprehensive review of the various forms of dystonia observed in patients with Parkinson's disease who can benefit from a therapeutic trial of botulinum toxin. Although most of these indications are not supported by randomized controlled clinical trials and, therefore, not approved by the Food and Drug Administration, there are many open-label trials supporting a large body of empirical experience testifying to the benefits of botulinum toxin treatment in these conditions.

Keywords: Parkinson’s disease; blepharospasm; botulinum toxin; cervical dystonia; dystonia.

PubMed Disclaimer

Conflict of interest statement

JJ has training or research grants from Abbvie Inc.; Dystonia Coalition; Merz Pharmaceuticals; and Revance Therapeutics Inc. He has served as a consultant for Abbvie Inc.; Aeon Biopharma; Neurocrine; Revance Therapeutics; and Teva Pharmaceutical Industries Ltd. JJ has received royalties from Cambridge; Elsevier; MedLink Neurology; Lippincott Williams and Wilkins; UpToDate; Wiley Blackwell and is a member of the following editorial boards: Expert Review of Neurotherapeutics; MedLink Neurology in Clinical Practice; Therapeutic Advances in Neurological Disorders; Neurotherapeutics; Toxins; Tremor and Other Hyperkinetic Movements; and Journal of Parkinson’s Disease. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Agarwal P. A. (2019). Severe jaw‐opening dystonia as an unusual manifestation of levodopa‐related wearing‐off in Parkinson's disease, and successful treatment with botulinum toxin injection. Mov. Disord. Clin. Pract. 6, 500–501. doi: 10.1002/mdc3.12782, PMID: - DOI - PMC - PubMed
    1. Albanese A., Bhatia K., Bressman S. B., Delong M. R., Fahn S., Fung V. S. C., et al. . (2013). Phenomenology and classification of dystonia: a consensus update. Mov. Disord. 28, 863–873. doi: 10.1002/mds.25475, PMID: - DOI - PMC - PubMed
    1. Albanese A., Bhatia K. P., Cardoso F., Comella C., Defazio G., Fung V. S. C., et al. . (2023). Isolated cervical dystonia: diagnosis and classification. Mov. Disord. 38, 1367–1378. doi: 10.1002/mds.29387, PMID: - DOI - PMC - PubMed
    1. Anandan C., Jankovic J. (2023). Botulinum toxin treatment in parkinsonism. J. Neurol. Sci. 456:122810. doi: 10.1016/j.jns.2023.122810 - DOI - PubMed
    1. Artusi C. A., Bortolani S., Merola A., Zibetti M., Busso M., De Mercanti S., et al. . (2019). Botulinum toxin for Pisa syndrome: an MRI-, ultrasound- and electromyography-guided pilot study. Parkinsonism Relat. Disord. 62, 231–235. doi: 10.1016/j.parkreldis.2018.11.003, PMID: - DOI - PubMed

LinkOut - more resources